<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00222027</url>
  </required_header>
  <id_info>
    <org_study_id>0200701</org_study_id>
    <secondary_id>PHRC</secondary_id>
    <nct_id>NCT00222027</nct_id>
  </id_info>
  <brief_title>Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial</brief_title>
  <acronym>GRAALL2003</acronym>
  <official_title>GRAALL 2003 Trial (ALL 15-59 Years). Feasibility of Risk-Adapted Therapy in Young Adult Acute Lymphoblastic Leukemia: a Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Several prognostic predictors, including baseline ALL features and response to initial
      therapy, have been described in adult ALL raising the issue of whether these predictors might
      be redundant and which must be considered for treatment stratification. In the GRAALL-2003
      prospective Phase 2 study, we aim to hierarchize the following high-risk factors in
      Ph-negative ALL patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1) baseline (BL) : WBC30G/L in B-lineage, CNS involvement, MLL-AF4 and E2A-PBX fusions,
      haploidy/near-triploidy; 2) early response (ER) : corticoresistance after prophase (CsR),
      chemoresistance at Day 8 (ChR); all CsR and/or ChR patients are planned to receive higher
      doses of cyclophosphamide (HyperC) at Day 15 of induction; 3) induction response (IR) : no CR
      or Ig-TCR minimal residual disease (MRD) 10-2 after standard or HyperC induction. Allogeneic
      stem cell transplantation is proposed to patients with a donor and at least one BL, ER, or IR
      factor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hierarchical evaluation of baseline poor-prognosis factors and response to initial therapy in younger adults with ALL</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hematologic and non hematologic toxicity of induction, consolidation and late intensification.</measure>
  </secondary_outcome>
  <enrollment>300</enrollment>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collection of treatment-stratefying prognostic factors</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  15-59 years

          -  acute lymphoblastic leukemia newly diagnosed

          -  signed written informed consent

        Exclusion Criteria:

          -  Lymphoblastic lymphoma

          -  Acute lymphoblastic leukemia 3

          -  Chronic Myeloid Leukemia acutisation

          -  Sever organ condition
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Françoise HUGUET-RIGAL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service d'Hématologie Clinique, Hôpital Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>January 6, 2009</last_update_submitted>
  <last_update_submitted_qc>January 6, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 7, 2009</last_update_posted>
  <responsible_party>
    <name_title>LLAU Marie-Elise</name_title>
    <organization>University Hospital Toulouse</organization>
  </responsible_party>
  <keyword>Acute lymphoblastic leukemia</keyword>
  <keyword>adult patient</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>Young adult patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

